このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Aligos Therapeutics 配当金

配当金基準チェック /06

Aligos Therapeutics配当金を支払った記録がありません。

主要情報

n/a

配当利回り

n/a

配当性向

業界平均利回り	2.9%
次回配当支払日	n/a
配当落ち日	n/a
一株当たり配当金	n/a
一株当たり利益	-US$1.27
3年後の配当利回り予想	n/a

最近の配当金アップデート

更新なし

Recent updates

Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) 27% Dip In Price Shows Sentiment Is Matching Revenues

May 24

Aligos Therapeutics, Inc. (NASDAQ:ALGS) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Apr 09

Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) Share Price Is Matching Sentiment Around Its Revenues

Feb 23

Here's Why We're Watching Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation

Oct 24

We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully

Jul 17

We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully

Mar 11

Aligos Therapeutics begins 12-week dosing in phase 1b study to treat hepatitis B

Jul 25

We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate

Jul 11

We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate

Feb 02

Here's Why We're Not Too Worried About Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation

Oct 19

Aligos Therapeutics EPS beats by $0.16

May 10

We're Hopeful That Aligos Therapeutics (NASDAQ:ALGS) Will Use Its Cash Wisely

May 01

What Is The Ownership Structure Like For Aligos Therapeutics, Inc. (NASDAQ:ALGS)?

Jan 16

Dosing underway for Aligos Therapeutics' hepatitis B candidate in early-stage study

Oct 30

決済の安定と成長

配当データの取得

安定した配当: ALGSの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。

増加する配当: ALGSの配当金が増加しているかどうかを判断するにはデータが不十分です。

配当利回り対市場

Aligos Therapeutics 配当利回り対市場

ALGS 配当利回りは市場と比べてどうか？
セグメント	配当利回り
会社 (ALGS)	n/a
市場下位25% (US)	1.5%
市場トップ25% (US)	4.7%
業界平均 (Biotechs)	2.9%
3年後のアナリスト予想 (ALGS)	n/a

注目すべき配当: ALGSは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。

高配当: ALGSは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。

株主への利益配当

収益カバレッジ: ALGSの配当性向を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。

株主配当金

キャッシュフローカバレッジ: ALGSが配当金を報告していないため、配当金の持続可能性を計算できません。

Aligos Therapeutics 配当金

配当金 基準チェック /06

主要情報

最近の配当金アップデート

Recent updates

Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) 27% Dip In Price Shows Sentiment Is Matching Revenues

Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2A Herald Study for the Treatment of Mash

First quarter 2024 earnings released: US$0.22 loss per share (vs US$0.54 loss in 1Q 2023)

Aligos Therapeutics, Inc., Annual General Meeting, Jun 27, 2024

Aligos Therapeutics, Inc. (NASDAQ:ALGS) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Aligos Therapeutics, Inc. Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects

Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies

Aligos Therapeutics, Inc. Announces the Initiation of the Phase 2a HERald Study of ALG-055009 in MASH Subjects

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Aligos Therapeutics, Inc. to Report Q4, 2023 Results on Mar 12, 2024

Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) Share Price Is Matching Sentiment Around Its Revenues

Aligos Therapeutics, Inc. Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009)

Aligos Therapeutics, Inc. Announces Executive Changes

Aligos Therapeutics, Inc. Presents Clinical and Nonclinical Data at the AASLD Liver Meeting®? 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New minor risk - Share price stability

Aligos Therapeutics, Inc. to Report Q3, 2023 Results on Nov 02, 2023

New major risk - Shareholder dilution

Aligos Therapeutics, Inc. announced that it has received $92.149997 million in funding from EcoR1 Capital, LLC, Deep Track Capital, LP, Armistice Capital LLC, Roche Venture Fund

Aligos Therapeutics, Inc. announced that it expects to receive $92.149997 million in funding from EcoR1 Capital, LLC, Deep Track Capital, LP, Armistice Capital LLC, Roche Venture Fund and other investors

Aligos Therapeutics, Inc. announced that it expects to receive $92.149997 million in funding from EcoR1 Capital, LLC, Deep Track Capital, LP, Armistice Capital LLC, Roche Venture Fund and other investors

Here's Why We're Watching Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation

Aligos Therapeutics Receives Non-Compliance Notice From Nasdaq

Aligos Therapeutics Receives Non-Compliance Notice From Nasdaq

Second quarter 2023 earnings released: US$0.43 loss per share (vs US$0.47 loss in 2Q 2022)

Aligos Therapeutics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully

New major risk - Revenue and earnings growth

Aligos Therapeutics Presents Data from Its Liver Disease Programs At the European Association for the Study of the Liver (Easl) Congress 2023

First quarter 2023 earnings released: US$0.54 loss per share (vs US$0.84 loss in 1Q 2022)

We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Price target increased to US$2.84

Aligos Therapeutics, Inc. on Track to Complete Phase 2-Enabling Activities in 2023 for its Clinically Validated THR-ß Drug Candidate for NASH, ALG-055009

Price target decreased to US$2.55

Consensus revenue estimates increase by 43%

Aligos Therapeutics Presents Clinical Data for Its Capsid Assembly Modulator, Alg-000184, At Aasld’S the Liver Meeting® 2022

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Aligos Therapeutics, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Aligos Therapeutics Initiates Dosing in Healthy Volunteers with siRNA Drug Candidate ALG-125755

Aligos Therapeutics, Inc. Files Response to Janssen Biopharma Lawsuit and Lodges Counterclaims Alleging Unfair Competition and Promissory Fraud

Consensus revenue estimates increase by 202%

Second quarter 2022 earnings released: US$0.47 loss per share (vs US$0.79 loss in 2Q 2021)

Aligos Therapeutics, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Aligos Therapeutics, Inc. Initiates 12-Week Dosing Cohort in Phase 1b Study Evaluating its Class II Capsid Assembly Modulator, ALG-000184

Aligos Therapeutics begins 12-week dosing in phase 1b study to treat hepatitis B

We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate

Aligos Therapeutics, Inc.(NasdaqGS:ALGS) dropped from Russell 2000 Growth Index

Aligos Therapeutics, Inc. to Participate in Metropolitan Antiviral Drug Accelerator, Recipient of NIH and NIAID Grant to Develop Therapeutics Against Coronaviruses and Pathogens of Pandemic Potential

First quarter 2022 earnings released: US$0.84 loss per share (vs US$0.74 loss in 1Q 2021)

Aligos Therapeutics to Present 28-Day Safety, Efficacy and Pharmacokinetic Data for CAM Drug Candidate ALG-000184 and Nonclinical Data for Two Additional Chronic Hepatitis B Programs

Aligos Therapeutics, Inc., Annual General Meeting, Jun 23, 2022

Price target decreased to US$6.10

Aligos Therapeutics Selects Drug Candidate ALG-097558, a Potent Ritonavir-Free Oral Protease Inhibitor for the Treatment and Prevention of COVID-19, to Advance into Development

Aligos Therapeutics, Inc. Receives Notice of A Complaint

Price target decreased to US$12.25

Aligos Therapeutics, Inc. to Report Q4, 2021 Results on Mar 10, 2022

We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate

Aligos Therapeutics Begins Dosing in Chronic Hepatitis B Patients in its Phase 1 Antisense Oligonucleotide Study (ALG-020572-401)

Price target decreased to US$19.20

Aligos Therapeutics, Inc. Halting Further Development of STOPS™ Drug Candidate, ALG-010133

Price target decreased to US$30.80

Aligos Therapeutics Begins Dosing with NASH Drug Candidate, ALG-055009, in Healthy Volunteers in A Phase 1 First-In-Human Study

Aligos Presents Update of Chronic Hepatitis B Pipeline Portfolio at HEP DART 2021

Here's Why We're Not Too Worried About Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation

Consensus revenue estimates increase to US$2.47m

Aligos Therapeutics, Inc.(NasdaqGS:ALGS) dropped from Russell Microcap Value Index

Aligos Therapeutics to Present Preliminary Antiviral Activity of ALG-000184 in Chronic Hepatitis B (CHB) Subjects

Aligos Therapeutics EPS beats by $0.16

We're Hopeful That Aligos Therapeutics (NASDAQ:ALGS) Will Use Its Cash Wisely

Aligos Therapeutics, Inc. Begins Dosing with STOPS Molecule Drug Candidate, ALG-010133, in First Cohort of Chronic Hepatitis B Patients in A Phase 1 Proof-Of-Concept Study

Aligos Therapeutics Presents Nonclinical Data for its COVID-19 Therapeutic in Development at the 2021 Conference on Retroviruses and Opportunistic Infections

What Is The Ownership Structure Like For Aligos Therapeutics, Inc. (NASDAQ:ALGS)?

Aligos Therapeutics, Inc. Presents Update on Development of SARS-CoV-2 Therapeutic Candidate and Screening Method in Collaboration with KU Leuven at RespiDART & Emerging Viruses 2020

配当金基準チェック /06